Compounds
One monograph per compound: identity, mechanism, the published evidence with its level, analytical characterisation, stability and dated regulatory status.
- BPC-157 and TB-500 blend: composition and analytical characterisation
Composition note for the two-component 30 mg preparation: what each compound is, how the split is recorded, and how one certificate of analysis carries a separate purity and identity line for each.
BPC-157 · reviewed 2026-09-22
- BPC-157: identity, the animal literature and regulatory status
A synthetic 15-residue peptide whose evidence base is almost entirely rodent studies. Identity, the animal literature by model, exactly what human data exist, and dated status.
BPC-157 · reviewed 2026-09-22
- CJC-1295 with DAC and without DAC: identity, evidence and status
Two molecules share the name CJC-1295: the albumin-binding DAC conjugate studied by ConjuChem and the tetrasubstituted GRF(1-29) sold without DAC. Identifiers for each, the small human literature in one table, and dated status.
CJC-1295 · reviewed 2026-09-22
- CJC-1295, ipamorelin and sermorelin blend: composition and analysis
Composition note for the three-component 30 mg preparation: what each compound is, how the split is recorded, and how one certificate of analysis carries a separate purity and identity line for each.
CJC-1295 · reviewed 2026-09-22
- GHK-Cu: copper tripeptide identity, evidence and regulatory status
Two substances answer to the name: the free tripeptide glycyl-L-histidyl-L-lysine and its 1:1 copper(II) complex. Separate identifiers for each, the in vitro, animal and cosmetic-study literature by evidence level, and dated status.
GHK-Cu · reviewed 2026-09-22
- Ipamorelin: identity, evidence and regulatory status
A selective pentapeptide growth hormone secretagogue with three non-proteinogenic residues, a closed postoperative-ileus programme, and no authorisation in the UK, the EU or the US.
Ipamorelin · reviewed 2026-09-22
- Retatrutide (LY3437943): identity, trial evidence and status
An investigational triple receptor agonist with no marketing authorisation anywhere: identifiers and the formula conflict, the phase 2 trials, the TRIUMPH readouts still unpublished, and dated status.
Retatrutide · reviewed 2026-09-22
- Semaglutide: identity, mechanism, trial evidence and status
A 31-residue acylated GLP-1 analogue: identifiers and side-chain chemistry, the albumin-binding protraction mechanism, eight phase 3 trials in one table, the published impurity literature and dated status.
Semaglutide · reviewed 2026-09-22
- Sermorelin: GRF(1-29) identity, evidence and a licence that ended
The amidated 1-29 fragment of human GHRH, once approved in the United States as Geref and discontinued in 2008. Identifiers for the free base and the acetate, the small clinical literature, and dated status in four jurisdictions.
Sermorelin · reviewed 2026-09-22
- TB-500 and thymosin β4: three molecules, one commercial name
TB-500 is a trade name applied to more than one substance: full-length thymosin β4, the N-acetylated 17-23 heptapeptide identified in analysed products, and the separate tetrapeptide Ac-SDKP.
TB-500 · reviewed 2026-09-22
- Tesamorelin: free base and acetate, trial evidence and status
A 44-residue GRF analogue acylated at Tyr1 and supplied as an acetate salt: the two identity records and what separates them, the Falutz and Stanley trials, and dated status in three jurisdictions.
Tesamorelin · reviewed 2026-09-22
- Tirzepatide: identity, dual receptor pharmacology and evidence
A 39-residue synthetic acylated peptide with dual GIP and GLP-1 receptor agonism: identifiers and side-chain chemistry, the SURPASS and SURMOUNT trials in one table, the analytical literature and dated status.
Tirzepatide · reviewed 2026-09-22